| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2021 | Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies | Berghoff A.S.; Sessa C.; CHIH-HSIN YANG ; Tsourti Z.; Tsang J.; Tabernero J.; Peters S.; Linardou H.; Letsch A.; Haanen J.; Garralda E.; Garassino M.C.; Furness A.J.S.; Felip E.; Dimopoulou G.; Dafni U.; Choo S.P.; Banerjee S.; Bajpai J.; Adjei A.A.; Garrido P. | ESMO Open | 7 | 3 | |
| 2021 | Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey | Garrido P.; Adjei A.A.; Bajpai J.; Banerjee S.; Berghoff A.S.; Choo S.P.; Felip E.; Furness A.J.S.; Garralda E.; Haanen J.; Letsch A.; Linardou H.; Peters S.; Sessa C.; Tabernero J.; Tsang J.; CHIH-HSIN YANG ; Garassino M.C. | ESMO Open | 13 | 11 | |
| 2020 | Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer | Peters S.; Shaw A.T.; Besse B.; Felip E.; Solomon B.J.; Soo R.A.; Bearz A.; Gadgeel S.M.; CHIA-CHI LIN ; Kao S.; Seto T.; Masters E.T.; Abbattista A.; Clancy J.S.; Thurm H.; Reisman A.; Peltz G.; Ross Camidge D. | Lung Cancer | 10 | 10 | |
| 2021 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer | Yoshino T.; Argil?s G.; Oki E.; Martinelli E.; Taniguchi H.; Arnold D.; Mishima S.; Li Y.; Smruti B.K.; Ahn J.B.; Faud I.; Chee C.E.; KUN-HUEI YEH ; Lin P.-C.; Chua C.; Hasbullah H.H.; Lee M.A.; Sharma A.; Sun Y.; Curigliano G.; Bando H.; Lordick F.; Yamanaka T.; Tabernero J.; Baba E.; Cervantes A.; Ohtsu A.; Peters S.; Ishioka C.; Pentheroudakis G. | Annals of Oncology | 20 | 20 | |
| 2020 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS | Park K.; Vansteenkiste J.; Lee K.H.; Pentheroudakis G.; Zhou C.; Prabhash K.; Seto T.; Voon P.J.; Tan D.S.W.; CHIH-HSIN YANG ; Wang J.; Babu K.G.; Nakayama Y.; Alip A.; Chua K.L.M.; CHIA-HSIEN CHENG ; Senan S.; Ahn Y.C.; Kim T.-Y.; Ahn H.K.; Peters S.; Yoshino T.; Douillard J.-Y. | Annals of Oncology | 50 | 49 | |
| 2020 | Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: Randomized, double-blind, phase III KEYNOTE-604 Study | Rudin C.M.; Awad M.M.; Navarro A.; Gottfried M.; Peters S.; Csoszi T.; Cheema P.K.; Rodriguez-Abreu D.; Wollner M.; CHIH-HSIN YANG ; Mazieres J.; Orlandi F.J.; Luft A.; G?m?? M.; Kato T.; Kalemkerian G.P.; Luo Y.; Ebiana V.; Pietanza M.C.; Kim H.R.; KEYNOTE-604 Investigators | Journal of Clinical Oncology | 262 | 229 |
